181300-40-3

Usage

Uses

Used in Pharmaceutical Industry:
(2-CHLORO-4-METHANESULFONYL-PHENYL)-METHANOL is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Organic Synthesis:
In the field of organic synthesis, (2-CHLORO-4-METHANESULFONYL-PHENYL)-METHANOL is employed as a versatile intermediate, enabling the creation of a variety of complex organic molecules for research and commercial applications.
Used in Drug Development:
(2-CHLORO-4-METHANESULFONYL-PHENYL)-METHANOL is utilized in drug development as a potential precursor for the creation of novel therapeutic agents, targeting a range of medical conditions and contributing to advancements in healthcare.

Upstream product

• 101349-95-5 2-chloro-4-(methylsulfonyl)benzaldehyde 
• 53250-83-2 2-chloro-4-(methanesulfonyl)benzoic acid 
• 84194-36-5 2-chloro-4-fluorobenzaldehyde 

Downstream Products

• 219764-95-1 2-Chloro-4-(methanesulfonyl)-1-((methanesulfonyloxy)methyl)benzene 
• 180200-86-6 1-(bromomethyl)-2-chloro-4-(methylsulfonyl)benzene 
• 101349-95-5 2-chloro-4-(methylsulfonyl)benzaldehyde 

Relevant academic research and scientific papers

Synthesis and crystal structure of [2-Chloro-4-(methylsulfonyl)phenyl]methanol

The crystal structure of the [2-chloro-4-(methylsulfonyl)phenyl]methanol has been determined by single crystal X-ray diffraction method. The crystal belongs to monoclinic, space group P2(1)/c, with a = 8.208(4), b = 4.870 (2), c = 23.349 (10) ?, α = 90, β = 97.160 (6), γ = 90°, V = 926.0 (7)?3, Z = 4, Dx= 1.583 Mg/m3, λ(MoKa) = 0.71073, F(000) = 456, μ(MoKα) = 0.607 mm-1, R = 0.0506 and wR = 0.1231 for 0.1263 reflections with I > 2σ (I). The S atom has a distorted tetrahedral geometry with bond angles ranging from 103.03 (12)° to 118.13 (13)°. The crystal structure is stabilized by intermolecular hydrogen bonds and p-p stacking interactions.

Piperidine compound and preparation method and medical application thereof

The invention discloses a piperidine compound shown as a formula (I) and a preparation method and medical application thereof, and particularly relates to a piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof and a preparation method and application of the piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof. The compound provided by the invention can inhibit the activity of USP7 enzyme, has very good selectivity and druggability, and can be used for preparing medicines for preventing or treating tumor diseases or virus infectious diseases.

ANTIPROLIFERATION COMPOUNDS AND USES THEREOF

The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

Click reaction as a tool to combine pharmacophores: The case of Vismodegib

Abstract The design and the preparation of a small library of 1,4-diphenyl-1,2,3-triazole derivatives is reported, with the aim to obtain a new class of Hedgehog pathway inhibitors. The smoothened protein is part of the hedgehog signaling pathway that is

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5a, R5b, R6a, R6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN

There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use in the manufacture of a medicament for the treatment of neuropathic pain.

1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS

The present invention relates to compound S of Formula (I).

ORGANIC COMPOUNDS

There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.